Kneat is a “hidden gem”, this investor says

Murray Wealth Group senior portfolio manager Michael Hakes said Kneat.com (Kneat Stock Quote, Chart, News, Analysts, Financials TSX:KSI) remains a “hidden gem” in Canada’s technology sector despite recent share weakness, pointing to the company’s role digitizing validation processes for global pharmaceutical and biotech manufacturers.

Speaking on BNN Bloomberg’s Market Watch on Dec. 1, he said Kneat’s software replaces the “full room of paper binders” required to document and test equipment in FDA-regulated drug facilities, moving life-sciences customers to a cloud-based, paperless system.

Hakes noted the stock had been a strong performer through early 2025, peaking near $7.00 in March before softening on “two quarters of ever-so-slightly weaker-than-expected revenue.” He said the underlying execution remains solid and sees the company returning to form as adoption expands across large life-sciences clients.

“We expect them to continue to execute going forward,” he said, adding that Kneat’s long runway for digital transformation supports a positive view over the next 18 to 24 months.

-30-